Dr Reddys Laboratories Sustainability Profile
Dr. Reddy's Laboratories, a prominent player in the global pharmaceutical industry, is headquartered in Hyderabad, India. Founded in 1984, the company has established itself as a leader in the development and manufacturing of a wide range of generic medications, active pharmaceutical ingredients (APIs), and proprietary products. With a strong presence in markets across North America, Europe, and Asia, Dr. Reddy's is committed to providing affordable healthcare solutions. The company’s core offerings include generic formulations, biosimilars, and over-the-counter products, distinguished by their quality and innovation. Dr. Reddy's has achieved significant milestones, including numerous product launches and strategic partnerships, solidifying its market position. Recognised for its commitment to sustainability and patient-centric approach, Dr. Reddy's Laboratories continues to make strides in enhancing global health outcomes.
DitchCarbon Score
How does Dr Reddys Laboratories's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Dr Reddys Laboratories's score of 91 is higher than 94% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Dr Reddys Laboratories's reported carbon emissions
In 2025, Dr. Reddy's Laboratories reported total greenhouse gas emissions of approximately 1,083,311,000 kg CO2e, comprising 142,772,000 kg CO2e from Scope 1, 94,690,000 kg CO2e from Scope 2, and 845,849,000 kg CO2e from Scope 3 emissions. The company has set ambitious climate commitments, aiming to reduce its Scope 1 and 2 emissions by 50.2% per million USD revenue by FY2031, which translates to a 25% absolute reduction from a FY2021 baseline. Additionally, Dr. Reddy's is targeting a 12.3% reduction in absolute Scope 3 emissions within the same timeframe. Looking towards the future, Dr. Reddy's Laboratories has committed to achieving net-zero greenhouse gas emissions across its value chain by FY2045. This includes a significant near-term goal of reducing absolute Scope 1 and 2 emissions by 80% by FY2030 from a FY2023 base year, and a similar 90% reduction target for both scopes by FY2045. For Scope 3 emissions, the company aims for a 90% reduction by FY2045, covering various categories such as purchased goods and services, business travel, and waste generated in operations. Dr. Reddy's Laboratories is actively working towards these targets, demonstrating a strong commitment to sustainability and climate action within the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 177,841,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 254,563,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 |
| Scope 3 | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
How Carbon Intensive is Dr Reddys Laboratories's Industry?
How Carbon Intensive is Dr Reddys Laboratories's Location?
Dr Reddys Laboratories's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Dr Reddys Laboratories has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Macleods Pharmaceuticals Limited
Frequently Asked Questions
Common questions about Dr Reddys Laboratories's sustainability data and climate commitments